Evidence map›Paper›PMID 40715479›Full record

ArticleThe Journal of antibiotics2025

New benzoyl sesquiterpenoid, aoganolide, produced by Talaromyces sp. KTF-0021 strain (laeA-introduced mutant of FKI-5759 strain).

Karin Hamada, Yoshihiro Watanabe, Yuta Kikuchi, Hayama Tsutsumi, Haruki Azami, Hiroki Kojima, Sho Kato, Akihiro Sugawara, Yuki Inahashi, Kenichi Nonaka and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in The Journal of antibiotics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Karin Hamada *Graduate School of Infection Control Sciences, Kitasato University, Minato-ku, Tokyo, Japan.
Yoshihiro Watanabe *Graduate School of Infection Control Sciences, Kitasato University, Minato-ku, Tokyo, Japan.ORCID 0000-0002-5756-0530
Yuta KikuchiGraduate School of Infection Control Sciences, Kitasato University, Minato-ku, Tokyo, Japan.
Hayama TsutsumiGraduate School of Infection Control Sciences, Kitasato University, Minato-ku, Tokyo, Japan.
Haruki AzamiGraduate School of Infection Control Sciences, Kitasato University, Minato-ku, Tokyo, Japan.
Hiroki KojimaGraduate School of Infection Control Sciences, Kitasato University, Minato-ku, Tokyo, Japan.
Sho KatoGraduate School of Infection Control Sciences, Kitasato University, Minato-ku, Tokyo, Japan.
Akihiro SugawaraGraduate School of Infection Control Sciences, Kitasato University, Minato-ku, Tokyo, Japan.ORCID 0000-0003-1266-7497
Yuki InahashiGraduate School of Infection Control Sciences, Kitasato University, Minato-ku, Tokyo, Japan.ORCID 0000-0001-7436-2037
Kenichi NonakaGraduate School of Infection Control Sciences, Kitasato University, Minato-ku, Tokyo, Japan.
Rei HokariGraduate School of Infection Control Sciences, Kitasato University, Minato-ku, Tokyo, Japan.
Aki IshiyamaGraduate School of Infection Control Sciences, Kitasato University, Minato-ku, Tokyo, Japan.ORCID 0000-0003-4703-8834
Yasuko ArakiResearch and Development Division, Kikkoman Corporation, Noda-shi, Chiba, Japan.
Kona YamashitaResearch and Development Division, Kikkoman Corporation, Noda-shi, Chiba, Japan.
Tadashi TakahashiResearch and Development Division, Kikkoman Corporation, Noda-shi, Chiba, Japan.
Kotaro ItoResearch and Development Division, Kikkoman Corporation, Noda-shi, Chiba, Japan.
Yukihiro AsamiGraduate School of Infection Control Sciences, Kitasato University, Minato-ku, Tokyo, Japan.ORCID 0000-0003-1821-9169
Masato IwatsukiGraduate School of Infection Control Sciences, Kitasato University, Minato-ku, Tokyo, Japan. iwatuki@lisci.kitasato-u.ac.jp.ORCID 0000-0001-8373-4314

Funding

Japan Agency for Medical Research and Development (AMED) JP21am0101096 (Phase I) and JP22ama121035 (Phase II)MEXT | Japan Society for the Promotion of Science (JSPS) JP20K07106 and JP23K06197MEXT | Japan Society for the Promotion of Science (JSPS) JP23H04880 and JP23H04884
6 · The paper itself

Abstract

To discover novel natural compounds by awakening unexplored or silent BGCs in fungi, our research group has explored the cultured broths of the laeA-introduced mutant fungal strains. In this study, we report the isolation of a new benzoyl sesquiterpenoid, aoganolide (4), as well as three known compounds, decarboxyaltenusin (1), altenusin (2), and penipyranicin B (3), from the cultured broth of Talaromyces sp. KTF-0021, which was a laeA-introduced mutant of FKI-5759 strain. The planar structure of 4 was elucidated by spectroscopic analysis and the absolute configuration of 4 was determined by the calculated ECD spectral method. Among them, 4 showed antimalarial activity with IC

Indexed as

AntimalarialsSesquiterpenesTalaromycesInhibitory Concentration 50Molecular StructureMutationPlasmodium falciparumAntimalarialsSesquiterpenes

Identifiers

PMID40715479

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.